The ACR Convergence Replay 2024 webinar series will include recorded sessions from ACR Convergence followed by a live Q&A with the presenters to answer your questions and provide further insights.

This session is about the latest advancements and challenges in the management of ANCA-associated vasculitis (AAV). Although treatment guidelines have become available, many questions persist about their specific application to different clinical scenarios and patient population with ANCA-associated vasculitis (AAV). In addition, recent evidence has reopened the debate about low versus standard dose glucocorticoids. An ongoing controversy about the use of plasmapheresis persists despite the findings of the PEXIVAS study. The use of avacopan has opened an opportunity for glucocorticoid minimization and remaining indications for cyclophosphamide are important to discuss.